ArticleThe Eurasian journal of medicine2026
Gut Microbiota and Thyroid Diseases.
Article in The Eurasian journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota plays a pivotal role in maintaining the homeostasis of the digestive and immune systems. Dysbiosis compromises the intestinal barrier and triggers systemic inflammation, thereby contributing to metabolic and immune dysregulation. Emerging evidence suggests a bidirectional relationship between the gut microbiota and thyroid function. The microbiota influences the absorption and metabolism of micronutrients essential for thyroid hormone synthesis, including iodine, selenium, iron, and zinc. Dysbiosis enhances intestinal permeability, facilitating the translocation of bacterial components into systemic circulation and potentially triggering autoimmune thyroid diseases (AITD) such as Hashimoto's thyroiditis and Graves' disease. Animal studies further demonstrate that hypothyroidism, hyperthyroidism, and thyroidectomy can alter the diversity and composition of gut microbiota. Environmental exposures such as particulate matter 2.5 reshape microbial and metabolic profiles, influencing the hypothalamus-pituitary-thyroid axis and thyroid hormone homeostasis. Clinical studies show reduced abundance of beneficial bacteria (Bifidobacterium and Lactobacillus) and enrichment of proinflammatory taxa in AITD patients. These findings highlight the complex bidirectional interactions between gut microbiota, thyroid function, and immune tolerance. Microbiotatargeted therapies may represent promising strategies for the prevention and management of thyroid disorders. This review aims to summarize current evidence regarding the bidirectional relationship between gut microbiota and thyroid disorders, with particular emphasis on dysbiosis, immune regulation, micronutrient metabolism, and autoimmune thyroid disease. Cite this article as: Beyhan YE, Işık Ş. Gut microbiota and thyroid diseases. Eurasian J Med. 2026, 58(3), 1232, doi: 10.5152/eurasianjmed.2026.251232.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.